Achieving Superior Treatment Durability and Outcomes in Neovascular AMD and DME

0:00 Introduction

0:52 Need for durable treatments in nAMD and DME

4:20 Mechanism of faricimab

7:10 Highlights from clinical trials for faricimab

10:28 Post hoc analyses of faricimab clinical trials

16:19 Factors affecting retreatment decision

19:20 Durability data for faricimab

23:22 Experience with faricimab

29:00 Choosing between faricimab and high-dose aflibercept

32:47 Final remarks